Evidence map›Paper›PMID 39798870›Full record

ArticleThe Journal of biological chemistry2025

N-terminal fragment shedding contributes to signaling of the full-length adhesion receptor ADGRL3.

Nicole A Perry-Hauser, Jonathan R Du Rand, Kuo Hao Lee, Lei Shi, Jonathan A Javitch

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Adhesion G protein-coupled receptors.Pharmacological reviews · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nicole A Perry-HauserDepartment of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA; Department of Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA; Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York, USA.
Jonathan R Du RandDepartment of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA; Department of Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA; Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York, USA.
Kuo Hao LeeComputational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, Maryland, USA.
Lei ShiComputational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, Maryland, USA.
Jonathan A JavitchDepartment of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA; Department of Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA; Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York, USA. Electronic address: jaj2@cumc.columbia.edu.

Funding

Structural basis for the functions of dopamine receptors, neurotransmitter transporters, and sigma 1 receptorZIADA000606 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SHI, LEI · 2015 to 2025
$20.5M
Structure of the Dopamine D2-Like Receptor Binding SitesR01MH054137 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI JAVITCH, JONATHAN A · 1995 to 2025
$12.0M
Research Training in Mood and Anxiety Disorders: From Animal Models to PatientsT32MH015144 · NIMH · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Eduardo David Leonardo · 1985 to 2026
$11.1M
Intramural NIH HHS ZIA DA000606NIMH NIH HHS R01 MH054137NIMH NIH HHS T32 MH015144
6 · The paper itself

Abstract

Most adhesion G protein-coupled receptors (GPCRs) undergo autoproteolytic cleavage during receptor biosynthesis, resulting in noncovalently bound N-terminal fragments (NTFs) and C-terminal fragments (CTFs) that remain associated during receptor trafficking to the plasma membrane. While substantial evidence supports increased G protein signaling when just the CTF is expressed, there is an ongoing debate about whether NTF removal is required to initiate signaling in the context of the WT receptor. Here, we use adhesion GPCR latrophilin-3 (ADGRL3) as a model receptor to investigate tethered agonist (TA)-mediated activation. First, we show that extending the N terminus of the TA in ADGRL3 CTF disrupts G protein signaling. This suggests that if the TA is not fully exposed, it is unlikely to interact with the orthosteric pocket in an optimal manner for G protein activation. Second, we show that when full-length ADGRL3 is expressed in heterologous cells, approximately 5% of the receptor population spontaneously sheds its NTF. We hypothesized that the signaling activity observed for full-length ADGRL3 is largely because of this shedding, which exposes the native TA. To test this hypothesis, we used a full-length cleavage-deficient ADGRL3 mutant. Compared with WT receptor, this mutant lost ∼80% of its signaling through Gα

Indexed as

Receptors, G-Protein-CoupledReceptors, PeptideSignal TransductionAnimalsHEK293 CellsHumansReceptors, G-Protein-CoupledReceptors, Peptideadhesion G protein–coupled receptor latrophilinadhesion G protein–coupled receptorsautoproteolysiscell signalingG proteinmembrane proteinreceptor reservetethered agonist

Identifiers

PMID39798870
PMCPMC11849108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.